RxSight stock plunges after slashing 2025 revenue guidance

RxSight (RXST) shares plummeted 28% after the ophthalmic medical device company significantly lowered its 2025 revenue guidance to $120-$130 million from a prior $160-$175 million, implying a potential 7-14% year-over-year decline. This drastic revision was primarily driven by a 49% year-over-year and 45% sequential drop in Light Delivery Device sales during Q2, which saw only 40 units sold. Despite raising gross margin guidance and reducing operating expense forecasts, the substantial top-line miss highlights significant underperformance in a key product segment, impacting the company's near-term outlook.

Analysis

RxSight (RXST) experienced a 28% stock price collapse following a severe downward revision of its full-year 2025 revenue guidance to $120-$130 million, a stark reduction from the previous forecast of $160-$175 million. This new guidance implies a potential year-over-year revenue decline of 7% to 14%, signaling a significant reversal in the company's growth trajectory. The revision was triggered by a deeply disappointing preliminary second quarter, where revenue fell 4% YoY to $33.6 million. The primary driver of this underperformance was a collapse in sales of its capital equipment, with Light Delivery Device (LDD) units falling 49% YoY and 45% sequentially to just 40 units sold. While the consumable Light Adjustable Lens sales grew 13% YoY, a 1% sequential dip raises concerns about slowing momentum in that segment as well. In response, management is pivoting its commercial strategy and implementing cost controls, evidenced by a reduced operating expense forecast and a slightly increased gross margin guidance to 72-74%. The company's strong cash position of $227.5 million provides a critical buffer to navigate this operational turmoil.

Key Decisions for Investors

• Investors should treat the stock with extreme caution, as the dramatic cut in revenue guidance and the collapse in LDD sales signal a fundamental breakdown in the company's commercial execution and growth narrative.
• The announced pivot in commercial strategy is now the central thesis; any potential long position is a high-risk bet on a successful turnaround, supported only by the strong cash balance and management's ability to stabilize LDD sales.
• Monitor LDD unit sales in subsequent quarters as the primary indicator of recovery, while also watching for any further deceleration in the higher-margin lens consumables, as a slowdown there would negate a key remaining strength.